SmartPill GI Monitoring System Brochure
Our evidence. Your expertise.
SmartPill®: The data you need to evaluate motility disorders.
Evaluate unexplained symptoms with one test.
Functional gastrointestinal (GI) symptoms are common in the general population with a reported prevalence of 25-40%, accounting for up to 40% of GI office consultations. Often, patients presenting with functional GI symptoms have evidence of a diffuse GI motility disorder.1 Upper and lower gut symptoms often overlap, therefore localizing transit abnormalities to a specific GI region is important in diagnostic evaluation and should be done early in the process to guide appropriate therapy.2
Constipation, one of the most common functional GI disorders, affects
12-19% of the population. Consequently, in 2001 U.S. constipationrelated healthcare costs averaged approximately $235 million, with a mean annual cost of $7,522 per patient.3
The SmartPill Motility Procedure – the latest advance in GI tract evaluation – can help. SmartPill collects data from the entire GI tract and provides the necessary information to thoroughly evaluate your patients.
With SmartPill you retain patient control and expand your practice capabilities, eliminating the dependency on radiology.
N
CONST
IPA
NIC
TI
RO
H
O
C
G
A
S
CONSTIPATION
CONSTIPATION
DIARRHEA
ABDOMINAL
PAIN
STOMACH
SPASMS
BLOATING
WEIGHT
LOSS
NAUSEA
EARLY SATIETY
VOMITING
1. Bonapace ES, Parkman HP, et al.: Whole Gut Transit Scintigraphy in the Clinical Evaluation of Patients with Upper and Lower Gastrointestinal Symptoms. The American Journal of Gastroenterology 2000; 95: 2838
N
CT
ION
AL DYS
PE
• Test standardization
• Provides direct access to GI motility data
SmartPill benefits your patients:
• More comfortable than existing diagnostic tests
• Well-tolerated – eliminates radiation exposure
• Ambulatory – performed under real-life conditions
SmartPill allows you to obtain data from the entire
GI tract in one test.
The SmartPill GI Monitoring System measures
SmartPill®: The data you need to evaluate motility disorders.
Evaluate unexplained symptoms with one test.
Functional gastrointestinal (GI) symptoms are common in the general population with a reported prevalence of 25-40%, accounting for up to 40% of GI office consultations. Often, patients presenting with functional GI symptoms have evidence of a diffuse GI motility disorder.1 Upper and lower gut symptoms often overlap, therefore localizing transit abnormalities to a specific GI region is important in diagnostic evaluation and should be done early in the process to guide appropriate therapy.2
Constipation, one of the most common functional GI disorders, affects
12-19% of the population. Consequently, in 2001 U.S. constipationrelated healthcare costs averaged approximately $235 million, with a mean annual cost of $7,522 per patient.3
The SmartPill Motility Procedure – the latest advance in GI tract evaluation – can help. SmartPill collects data from the entire GI tract and provides the necessary information to thoroughly evaluate your patients.
With SmartPill you retain patient control and expand your practice capabilities, eliminating the dependency on radiology.
N
CONST
IPA
NIC
TI
RO
H
O
C
G
A
S
CONSTIPATION
CONSTIPATION
DIARRHEA
ABDOMINAL
PAIN
STOMACH
SPASMS
BLOATING
WEIGHT
LOSS
NAUSEA
EARLY SATIETY
VOMITING
1. Bonapace ES, Parkman HP, et al.: Whole Gut Transit Scintigraphy in the Clinical Evaluation of Patients with Upper and Lower Gastrointestinal Symptoms. The American Journal of Gastroenterology 2000; 95: 2838
N
CT
ION
AL DYS
PE
• Test standardization
• Provides direct access to GI motility data
SmartPill benefits your patients:
• More comfortable than existing diagnostic tests
• Well-tolerated – eliminates radiation exposure
• Ambulatory – performed under real-life conditions
SmartPill allows you to obtain data from the entire
GI tract in one test.
The SmartPill GI Monitoring System measures